PHB-050

DB32061ExperimentalProtein Based Therapies

PHB-050 is an investigational next-generation anti-IgE monoclonal antibody designed to bind soluble IgE, deplete circulating IgE levels, and inhibit IgE production for the treatment of IgE-mediated atopic diseases. PHB-050 is a novel, next-generation anti-IgE antibody designed to block IgE from binding to mast cells, while also rapidly reducing circulating IgE and inhibiting its production.

Mechanism: Pharmacologically active on Immunoglobulin heavy constant epsilon
Curator reviewed
Code names: CX-10759 · PHB-050

Resolves to

Targets

P01854IGHE

What you can answer from here — as of January 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with PHB-050, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account